Live Analyst Rating Changes 35724 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/James Condulis
STIF

James Condulis

Stifel Nicolaus
Wall Street Analyst
★★★☆☆
#1856
on 13Foresight · ranked by our own returns
36%
Success Rate
+1.1%
Average Return
9 of 25 calls profitable · +31.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 36% of James Condulis's ratings turned a profit when each position was held for 1 year — averaging +1.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

39 Buy 9 Hold 0 Sell
James's Stock Coverage 11 ratings · 2026-09-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
FULC
Fulcrum Therapeutics
 Sep 21, 2026 HOLD Hold
+170.3% avg upside
14 analysts
 — -1.6% ·
BRVE
Braveheart Bio, Inc.
 Sep 09, 2026 BUY Strong Buy
+97.7% avg upside
5 analysts
$45.00
110.82% Upside
 -27.1% ·
NAMS
NewAmsterdam Pharma Company
 Sep 08, 2026 BUY Strong Buy
+100.5% avg upside
19 analysts
$50.00
113.70% Upside
 -5.1% ·
ARWR
Arrowhead Pharmaceuticals
 Aug 31, 2026 BUY Strong Buy
+9.9% avg upside
28 analysts
$104.00
60.07% Upside
 -20.5% ·
AMLX
Amylyx Pharmaceuticals Inc
 Aug 18, 2026 BUY Strong Buy
+27.1% avg upside
14 analysts
 — -16.6% ·
AARD
Aardvark Therapeutics, Inc.
 Aug 13, 2026 HOLD Buy
+261.8% avg upside
12 analysts
$6.00
13.29% Upside
 -16.2% ·
EWTX
Edgewise Therapeutics
 Aug 11, 2026 HOLD Strong Buy
+14.7% avg upside
15 analysts
$36.00
7.21% Downside
 -10.4% ·
TECX
Tectonic Therapeutic
 Aug 07, 2026 BUY Strong Buy
+133.8% avg upside
24 analysts
$75.00
226.82% Upside
 -23.6% ·
XFOR
X4 Pharmaceuticals
 Aug 07, 2026 BUY Strong Buy
+722.8% avg upside
16 analysts
$10.00
237.35% Upside
 -35.1% ·
CYTK
Cytokinetics
 Aug 07, 2026 BUY Strong Buy
+38.3% avg upside
36 analysts
$108.00
66.87% Upside
 -14.5% ·
MIRM
Mirum Pharmaceuticals
 Aug 06, 2026 BUY Strong Buy
+35.6% avg upside
23 analysts
$136.00
55.51% Upside
 -9.2% ·
🔒 6 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
James Condulis — Frequently Asked Questions
How accurate are James Condulis's stock ratings?
Based on the calls 13Foresight could measure, about 36% of James's ratings were profitable over a one-year hold, with an average return of +1.0% per rating, or +31.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is James ranked on 13Foresight?
James Condulis is currently ranked #1856 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on FULC, BRVE, NAMS, ARWR, AMLX, AARD, EWTX, TECX, XFOR, CYTK, MIRM. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.